Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 5/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647715 | 0.88 | PDE7A (0.40) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6649155 | 0.88 | PDE7A (0.41) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6649216 | 0.85 | CASP3 (0.44) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6642943 | 0.85 | PDE7A (0.40) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6646611 | 0.83 | SCN10A (0.46) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6644233 | 0.83 | MAPT (0.55) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6646845 | 0.80 | EIF2AK3 (0.42) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6642104 | 0.79 | SCN10A (0.44) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6645438 | 0.79 | SCN10A (0.42) | PDE7ASCN10AMAPTTP53SMN1; SMN2 | |
| SCHEMBL6648859 | 0.79 | SCN10A (0.41) | PDE7ASCN10AMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | PDE7A 3143/4885SCN10A 1201/4885MAPT 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.